MiNK Therapeutics, Inc. (INKT)

Market Cap	58.14M +94.8%
Revenue (ttm)	n/a
Net Income	-12.47M
EPS	-2.78
Shares Out	4.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,601
Open	11.70
Previous Close	11.46
Day's Range	11.57 - 11.95
52-Week Range	6.80 - 76.00
Beta	0.47
Analysts	Strong Buy
Price Target	39.00 (+234.19%)
Earnings Date	Aug 13, 2026

About INKT

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients wit...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2021
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: INKT
• Website: https://minktherapeutics.com

Analyst Summary

According to 2 analysts, the average rating for INKT stock is "Strong Buy." The 12-month stock price target is $39.0, which is an increase of 234.19% from the latest price.

Price Target

$39.0

(234.19% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 3, 2026

Data Sources Report a data error